Skip to content
AnalystLens

Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2006

Filing Date
Filed March 9, 2007
Period End
December 31, 2006
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Mar ’18Mar ’18
  2. FY2019 annual report10-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 10-K filed March 9, 2007. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. (filed under the name shown in the filing) is a biopharmaceutical company developing and commercializing recombinant human enzymes for drug delivery, palliative care, oncology, and infertility.

Its technology is based on recombinant human PH20 (rHuPH20), a human synthetic version of hyaluronidase. In fiscal 2006 the company had total revenues of $981,746a against total expenses of $16,564,602, resulting in a net loss of $14,751,986, or $0.24 per share. Accumulated deficit stood at $41,099,240 as of December 31, 2006, and the company has never been profitable.

Cash and cash equivalents rose to $44.2 millionb at year-end 2006, which the filing attributes primarily to a $20.0 million upfront payment from Roche and $11.0 million from a common stock sale to a Roche affiliate, plus $7.3 million from warrant and option exercises. The company states that its current cash will be sufficient to fund operations for at least the next twelve months. The company's commercial position is still early.

Cumulase, its IVF product, and Hylenex, approved by the FDA in December 2005, generated limited revenue, with Cumulase product sales of $342,000c and Hylenex API sales of $329,000 in 2006. In December 2006, Roche licensed Enhanze Technology for up to thirteen targets, with up to $111 million in potential milestones on the first three targets. In February 2007, Baxter amended its Hylenex agreements, paid a $10 million upfront payment, and may make milestone payments of up to $25 million, while Baxter will now assume development, manufacturing, and marketing costs for the covered products.

Chemophase, the lead oncology candidate, is in a Phase I/IIa trial for superficial bladder cancer. Key risks highlighted in the filing include dependence on a sole contract manufacturer (Avid Bioservices) and a single fill-and-finish partner for Hylenex, competition from animal-derived hyaluronidase products, the possibility that the company will need to raise additional capital, and the dilutive effect of about 6.4 million outstanding warrants.

Key Highlights

  1. Net loss of $14,751,986 ($0.24 per share) for 2006, compared with $13,275,373 ($0.26 per share) in 2005; total revenues were $981,746.
  2. Cash and cash equivalents of $44,189,403 at December 31, 2006, up from $19,132,194 a year earlier.
  3. Roche license and collaboration agreement (December 2006) for Enhanze Technology included a $20 million upfront payment and potential milestones of up to $111 million on the first three targets.
  4. Baxter amended Hylenex agreements in February 2007, with a $10 million upfront payment and potential milestones of up to $25 million; Baxter will assume development, manufacturing, and marketing costs for covered products.
  5. Accumulated deficit of $41,099,240 as of December 31, 2006; the company states it has never been profitable.
  6. Company believes current cash will fund operations for at least the next twelve months, but may need to raise additional capital, with about 6.4 million warrants outstanding.
  7. Relies on a sole contract manufacturer (Avid Bioservices) for active pharmaceutical ingredient and on Baxter for Hylenex fill and finish, both identified as concentration risks.

Frequently Asked Questions

  1. What drove the increase in cash during 2006?

    Cash and cash equivalents increased by $25.1 million to $44.2 million, primarily due to the $20.0 million initial upfront payment from Roche, $11.0 million in net proceeds from the sale of common stock to Roche, and $7.3 million from warrant and stock option exercises, offset by operating cash use and capital expenditures.

  2. How much revenue did Halozyme generate from its approved products in 2006?

    Product sales were $671,000 in 2006, consisting of Cumulase product sales of $342,000 and sales of the Hylenex active pharmaceutical ingredient of $329,000. Revenue under collaborative agreements was $311,121.

  3. What are the financial terms of the Roche and Baxter agreements?

    Roche paid a $20 million initial upfront payment and may pay milestones of up to $111 million on the first three targets, plus royalties, with additional upfront and milestone payments of up to $47 million per target for ten further targets. Baxter paid a $10 million initial upfront payment and may pay milestones of up to $25 million, plus royalties; Baxter also prepaid $1 million of royalties and will prepay $9 million more by January 1, 2009.

  4. What are the main risks for investors?

    The filing cites a history of losses and the possibility the company never becomes profitable, the need to raise additional capital that may dilute shareholders, regulatory approval uncertainty for product candidates, dependence on a sole contract manufacturer and third-party fill-and-finish partners, competition from animal-derived hyaluronidase products, and potential stock price volatility.